May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
Comparison of Comorbid Conditions Between Wet AMD Patients and a Control Cohort in the Medicare Population
Author Affiliations & Notes
  • S. Shah
    Pfizer Inc., New York, NY
  • G. Zlateva
    Pfizer Inc., New York, NY
  • S. Zhou
    Pfizer Inc., New York, NY
  • J.C. Javitt
    Wilmer Ophthalmological Institute, Johns Hopkins School of Medicine, Baltimore, MD
  • Footnotes
    Commercial Relationships  S. Shah, Pfizer, E; G. Zlateva, Pfizer, E; S. Zhou, Pfizer, E; J.C. Javitt, (OSI) Eyetech, C.
  • Footnotes
    Support  Supported by Pfizer Inc.
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 2209. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Shah, G. Zlateva, S. Zhou, J.C. Javitt; Comparison of Comorbid Conditions Between Wet AMD Patients and a Control Cohort in the Medicare Population . Invest. Ophthalmol. Vis. Sci. 2006;47(13):2209.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To compare prevalence rates and relative risk of comorbidities between patients with Wet age–related macular degeneration (AMD) and a control group without Wet AMD

Methods: : This observational retrospective study consisted of 2003 Medicare beneficiaries that were included in the standard 5% analytic sample excluding, however, those enrolled in a Medicare Managed Care plan. The database provides information for Medicare Part A and B coverage, HMO participation, date of death, and some demographic information including race. The cohort of Wet AMD included those 65 years of age or older with a diagnoses code for AMD, defined by the International Classification of Diseases (ICD–9 of 362.52, 362.42, or 362.43). The control group with no Wet AMD was age and gender matched to the comparison group. A selection of the 13 most common comorbid conditions was identified based on the general population and those that are Wet AMD related (cancer, diabetes, lipids, nervous system, hypertension, stroke, respiratory system, GI disorder, skin disorders, musculoskeletal disease, external injury, depression, and bone fracture). Prevalence rates were calculated and odds ratios were analyzed using logistic regression to understand the risk for comorbid conditions.

Results: : For all of the comorbidities evaluated, the prevalence rate for the Wet AMD cohort was significantly higher than the control group except for those with bone fracture which was similar. The risk of stroke was 11.6% higher in the Wet AMD group than the control cohort. Wet AMD patients also had a significanlty higher risk of hypertension and lipid disorders at 31.5% and 36.4% respectively. Patients with depression were 11.4% higher in the Wet AMD group compared to the control cohort.

Conclusions: : Medicare–aged patients typically have many comorbid conditions. These data demonstrated that patients with Wet AMD have significantly greater prevalence rates of these common comorbid conditions. Wet AMD patients should be given medications that are safer with less risk of side effects and cardiovascular events in order to help maintain their health.

Keywords: aging • age-related macular degeneration • clinical (human) or epidemiologic studies: prevalence/incidence 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.